TrialJournal for immunotherapy of cancer2026
Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma.
Evan Rosenbaum et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it